) The Biostatistics Core provides the resource for biostatistical and data management services for the Program Project. These services are divided into the following areas of responsibility. (1) Biostatistical consultation including: providing statistical advice for the design of new studies and analyses for the projects proposed in this through collaboration with each laboratory and clinical investigator on the statistical and scientific aspects of planned protocols, including review and approval of protocols by the biostatistician before submission to the IRB and subsequent activation. (2) Produce randomization tables and establish registration procedures in the Duke Cancer Center Protocol office for randomized clinical trials. (3) Assist with preparation of analyses for seminars, national and international meetings and for publication in scientific journals. (4) Create, collect, maintain and validate databases for the investigational and clinical studies by providing quality controlled data management. (5) Provide programs to collect and transfer data electronically to decrease manual data collection and data entry. This capacity includes the management of the dedicated computer, including computer systems for data storage and access, development of systems improvements, computer space management, computer administration, trouble shooting, collaboration in report development and collaboration in training of data managers, investigators and other personnel; (6) Prepare interim data reports for ongoing clinical studies and to monitor early stopping rules. The Biostatistical Core has an established team in place. Computer and data systems have been developed and are operational for fulfilling the missions described above. The team is composed of a Principal Investigator, Biostatistician and Systems Manager (all experienced in planning and analyzing clinical trials) and a Data Manager Supervisor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047741-09
Application #
6300321
Study Section
Project Start
2000-01-18
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
2000
Total Cost
$115,156
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Brennan, Todd V; Lin, Liwen; Huang, Xiaopei et al. (2018) Generation of Luciferase-expressing Tumor Cell Lines. Bio Protoc 8:
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
Rowland, Christopher R; Colucci, Lina A; Guilak, Farshid (2016) Fabrication of anatomically-shaped cartilage constructs using decellularized cartilage-derived matrix scaffolds. Biomaterials 91:57-72
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Brennan, Todd V; Lin, Liwen; Brandstadter, Joshua D et al. (2016) Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest 126:207-19
Sung, Anthony D; Sung, Julia A M; Thomas, Samantha et al. (2016) Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 63:999-1006

Showing the most recent 10 out of 132 publications